Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin.
The aim of our study was to investigate the role of electroporation in the treatment of cisplatin resistant tumor cells in vitro. For this purpose we used well characterized human ovarian carcinoma IGROV I cells and their resistant subclone IGROV 1/DDP. The cells were either continuously exposed to cisplatin or treated with electrochemotherapy (exposure time: 5 minutes). After chronic exposure of cells to cisplatin, IGROV 1/DDP cells exhibited 8-fold resistance to cisplatin. Cisplatin cytotoxicity was greatly potentiated by treatment with electric pulses in both cell lines. However, the IGROV 1/DDP cells still exhibited a 50-fold resistance. Our results demonstrate that electroporation treatment potentiates cytotoxicity in both human ovarian carcinoma IGROV 1 cells as well as in their resistant subclone IGROV 1/DDP.
Cemazar
M
M
Institute of Oncology, Department of Tumor Biology, Ljubljana, Slovenia.
Sersa
G
G
Miklavcic
D
D
D002463:Cell Membrane Permeability; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000627:therapeutic use / Q000633:toxicity*; D002999:Clone Cells; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D004599:Electric Stimulation Therapy; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms; D014407:Tumor Cells, Cultured
D002945:Cisplatin